1. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial;Munro AP;Lancet,2021
2. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience;Gambichler T;J Eur Acad Dermatol Venereol,2022
3. Bullous pemphigoid: trigger and predisposing factors;Moro F;Biomolecules,2020
4. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies;Lo Schiavo A;Clin Dermatol,2013
5. Atypical presentations of bullous pemphigoid: clinical and immunopathological aspects;Cozzani E;Autoimmun Rev,2015